Where do Anti-TROP2 ADCs Factor into Advanced TNBC Care?
Making a Difference in Survival: Integrating New Therapies for Triple-Negative Breast Cancer
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.Start Activity
Upon completion of this activity, participants will be able to:
-Discuss new targeted treatment approaches in the setting of TNBC
-Discuss the role of ADC therapies and TROP2 for triple-negative breast cancer
Breast Oncology Nurse Practitioner
Breast Cancer Center
UCSF Medical Center
San Francisco, CA
The University of Chicago Pritzker School of Medicine Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Other Healthcare Professional Credit
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.